Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells by Eberle, Irina et al.
Figure S1: Splice variants of the NANOG1 and NANOG2 gene 
 




































































































































































































All  cloned  and  sequenced  NANOG1  and  NANOG2  transcript  variants  are  summarized 
above. Exons are alternatively marked in red and in blue. Translation start and stop codons 




Exon 1a  intron  Exon 2 
GCGAAGAATGTA•gtaagtcggcct - cccttcccccag•AAACACACACAC 
 
Exon 1b  intron  Exon 2 
AGCTCAGCCTCG•gtgagtcttgtt - cccttcccccag•AAACACACACAC 
 
Exon 1b*  intron  Exon 2 
GTTTACTTTTCG•gtatggaagact - cccttcccccag•AAACACACACAC 
 
Exon 2  intron  Exon 3 
AAGGAAACTAAG•gtaggtgctgaa - ctatactaacAT•GAGTGTGGATCC (+3) 
                          - tactaacATGAG•TGTGGATCCAGC (+6) 
                          - GTGTGGATCCAG•CTTGTCCCCAAA (+17) 
 
Exon 3  intron  Exon 4 
ACACGGAGACTG•gtaagaaagaaa - tgttcccaacag•TCTCTCCTCTTC 
 
Exon 4  intron  Exon 5 
AGCTACAAACAG•gtaggcttgttt - tttttcctgcag•GTGAAGACCTGG 
 
Exon 5  intron  Exon 6 
GGTGTGACGCAG•gtaacaggaaac - cttctctttcag•AAGGCCTCAGCA 




Exon 1b  intron  Exon 3 
AGCTCAGCCTCG•gtgagtcttggt - taatgacATGAG•TGTGGATCCAGC (+6) 
                          - GTGTGGATCCAG•CTTGTCCATAAA (+17) 
Exon 1b* 
CAGAGTGGAGGT•ctgagaagaaaa - GGTCACCTATAC•CTGTGATTTGTG (+77) 
 
Exon 3  intron  Exon 4 
ACACAGAGACTG•gtaagaaagaaa - tgtttccaacag•TCTCTCCTCTTC 
                          - CTGCCTATTCAG•GACAGCCATGAT (+39) 
 
Exon 4  intron  Exon 5 
AGCTACAAACAG•gtaggcttattt - tttttcctgcag•GTGAAGACCTGG 
 
Exon 5  intron  Exon 6 
GGTGTGACGCAG•gtaacaggaaac - cttctctttgag•AAGGCCTCAGCA 
                          - TCCTACCACCAG•GGATGCCTGGTG (+48) 
 
Exon  sequences  are  marked  in  bold  letters  and  are  shown  for  both  the  NANOG1  and 
NANOG2 gene. Intronic sequences are in lower case letters. Exonic and intronic sequences 












































Cytospinned  SEM  and  RS4;11  cells  were  treated  with  HRP-conjugated  antisera 
raised against NANOG, OCT4 and SOX2. Counterstainings were performed with a 
DAPI solution. Controls were treated with all solutions except the antisera. A few 
SEM cells seem to express NANOG, while OCT4 and SOX2 seem to be expressed 
in nearly all cells. RS4;11 cells seems to express NANOG and SOX2, while only few 
cells express OCT4. 

















Primer A-B: ~10.000 copies
Primer C-D: ~1.000.000 copies
Formula:
A-B: transcripts starting from 
NANOG1 ex 1b = a
C-D: transcripts starting NANOG1 
ex 1b, NANOG1 ex 3, NANOG2 ex 






if a = 10.000
and 2a + 2b = 1.000.000










Top:  partial  gene  structure  of  NANOG1  and  NANOG2  (exons  1-4).  Nomenclature  as  in 
Figure 2 of the manuscript. QPCR-primer design: primer A binds to NANOG1/2 exon 1b, 
primer B to NANOG1 exon 2, primer C to NANOG1/2 exon 3 and primer D to NANOG1/2 
exon  4.  Lower  left  panel:  Results  of  independent  QPCR  experiments  made  with  reverse 
transcribed  total  RNA  isolated  from  NTERA2  cells.  The  experiments  were  carried  out  as 
described  in  Material  and  methods.  All  experiments  were  carried  out  in  parallel  with  log-
diluted plasmid copies (1 – 10
6 copies) that encode the NANOG1Bb splice variant. Lower 
right panel: Primers AB create an amplimer specific for the NANOG1 gene, while primers CD 
are able to identify transcripts starting from both NANOG genes (4 different transcripts), we 
estimated roughly the relative amount of transcripts starting from NANOG1 ex1b in relation to 












































A.  Outline  of  the  performed  RNase  protection  experiments.  Radiolabeled  antisense  RNA 
probes were generated with the MAXIscript Kit (AMBION). For NANOG1 we used a cloned 
exon 2-3 fragment (∆5 splice variant); for NANOG2 we used a cloned exon 1-3-4 fragment 
(∆5  splice  variant).  Both  fragments  were  cloned  in  pGEM-T  plasmid  (Promega);  plasmid 
were  digest  and  subjected  to  SP6  polymerase  transcription  in  the  presence  of 
32P-UTP 
nucleotides. Radioactive labeled probes were separated on a 5% denaturating PAA gel. Gel 
slices  were  cut  out  and  eluated  over  night  at  37°C.  Eluated  RNA  probes  were  then 
precipitated and dissolved into 40.000 cpm/µl. 
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BB. RNase protection experimente were carried out as recommendend by the manufacturer 
(AMBION). Briefly, we used 10 and 30 µg total RNA from NTERA2 cells. About 80.000 cpm 
were co-precipitated with these RNAs. Appropriate controls were performed by suing yeast 
RNA.  
B. NTERA cells express both the NANOG1 and NANOG2 gene. Due to our NANOG1-probe, 
3  different  protected  species  were  expected.  A  277  nucleotide-long  species  proves  that 
transcripts spanned exons 2 and 3, while the shorter 130 nucleotide-long species represents 
transcripts starting upstream of NANOG exon 3. The shortest 119 nucleotide-long species is 
indicative  for  a  splice  product  from  exon  2  to  nucleotide  +17  of  exon  3.  Thus,  NANOG1 
transcripts in NTERA2 cells are starting upstream of the 5’ terminal nucleotide of the 277 
protected fragment in exon 2 and predominantly splice to nucleotide +17 of exon 3. 
Due  to  our  NANOG2-probe,  5  different  protected  species  were  expected.  The  longest 
protected fragment is indicative for the presence of NANOG2 transcripts coding for exons 1b, 
3  and  4.  The  223  nucleotide-long  fragment  represents  NANOG2  transcripts  starting 
upstream of NANOG exon 3 and containing exon 4 sequences. The 212 nucleotide-long 
species represents again a splice variant from NANOG2 exon 1b to nucleotide +17 of exon 
3. The 146 nucleotide-long species are again transcripts starting upstream of exon 3, but are 
alternatively splice to nucleotide +39 of exon 4. The shortest protected fragment with 135 
nucleotides represents transcripts starting from exon 1b that alternative splice to nucleotide 
+17  of  exon  3  and  alternatively  to  nucleotide  +39  of  exon  4.  Thus,  transcripts  starting 
upstream of NANOG exon 3 are predominantly used in NTERA2 cells. 
In summary, this experiment validated independently the existence of NANOG1 exon 1b and 
2 and NANOG2 exon 1b in transcripts deriving from both genes. 
 














































A. Tested fragments I-III for NANOG1 and NANOG2 in ChIP experiments.  
B.  ChIP  experiments.  Chromatin  was  cross-linked  with  1%  formaldehyde  at  room 
temperature for 10 min in PBS. Cells were then washed twice with PBS, collected in SDS 
Buffer (100 mM NACl, 50 mM Tris pH 8.1, 5 mM EDTA pH 8.0, 0,5% SDS) and centrifuged 
for 6 min at 1.200 rpm. For sonication, cells were collected in IP Buffer (100 mM NaCl, 67 
mM Tris pH 8.3, 5 mM EDTA pH 8.0, 1,7% Triton X-100, 0,3% SDS) and sonicated 4 x 20 sec with an amplitude of 30%  (Branson Digital Sonifier W-250 D, Danbury, CT) followed by 
centrifugation for 50 min at 20.000 x g at 4°C. The chromatin was then pre-cleared with 
protein A/G-sepharose (25 µl of 50% slurry in TE buffer (Santa Cruz, CA), containing 2 µg of 
salmon sperm DNA (Trevigen USA), and 50 µg BSA) for 2-4 h at 4°C. Immunoprecipitations 
were performed overnight at 4°C with specific antibodies (Abcam, UK:ЋRNA polymerase II, 
ЋHistone H3-trimethyl K4,ЋHistone H3-trimethyl K9,ЋSox2; Santa Cruz, USA: ЋOct-3/4 
C-20, ЋIgG). After immunoprecipitation, 20 µl protein A-Sepharose with 1,6 µg of salmon 
sperm DNA and 40 µg BSA were added and the incubation was continued for another 2-3 h. 
Precipitates were washed sequentially three times with wash buffer (WB) 1 (150 mM NaCl, 
200 mM Tris pH 8.1, 50 mM EDTA pH 8.0, 5,2% sucrose, 1% Triton X-100, 0,2% SDS), two 
times with WB 2 (0,1% deoxycholic acid, 1 mM EDTA, 50 mM HEPES pH7,5, 500 mM NaCl, 
1% Triton X-100), two times with WB 3 (0,5% deoxycholic acid, 1 mM EDTA, 250 mM LiCl, 
0,5% NP-40, 10 mM Tris pH 8.0) and one time with TE Buffer. DNA was eluted by incubating 
the protein A-sepharose in 300 µl of 1% SDS, 0,1 M NaHCO3 overnight at 65°C, shaking. 
Proteins were removed by incubation with 60 µg of Proteinase K for 60 min. DNA fragments 
were purified with a QIAquick Spin Kit (Qiagen, Germany). The recovered DNA was then 
analyzed by PCR. All PCR experiments were performed in 50 µl reactions with the following 
setting: initial denaturation with 2 min at 94°C, followed by 35 cycles with 30 sec at 94°C, 30 
sec at 60°C and 30 sec at 72°C. A final elongation step (3 min at 72°C) was used for all 
reactions.  The  following  oligonucleotides  were  used:  NANOG1  fragment  I  (5’-
cagggtaccatctgctcactaagtgttag-3’;  5’-cagaagcttgttaaaatgagctaacggct-3’);  NANOG1  fragment 
II (5’-cagggtacccgtgcccagccgttag-3’; 5’-cagaagcttctttgcataaaagcctgag-3’); NANOG1 fragment 
III (5’-cagggtaccatcccattcctgttga-3’; 5’-cagaagcttctggatccacactcatgt-3’); NANOG2 fragment I 
(5’-cagggtaccatctgctcactaagtgttag-3’;  5’-cagaagcttgttaaaatgagctaacaatttag-3’);  NANOG2 
fragment  II  (5’-cagggtacctcaactctactaaattgttag-3’;  5’-cagaagcttctttgcataaaagcctgag-3’); 
NANOG2  fragment  III  (5’-cagggtaccgtgctggaacccaactct-3’;  5’-cagaagcttctggatccacactcatgt-
3’). 

























A. Tested NANOG1/2 DNA fragments. Different reporter plasmids containing the NANOG1-I 
to  III  and  NANOG2-I  to  III  regions  were  cloned  into  the  pGL3-Luciferase  plasmid.  The 
promoter-less pGL3-Basic vector was used as negative control. 
B.  Luciferase  reporter  assays.  All  constructs  were  transiently  co-transfected  in  1  x  10
5 
NTERA2 cells by using Lipofectamin-transfection. NTERA-2 cells were electroporated with 1 
µg  of  each  of  the  pGL-3  constructs  together  with  25  ng  pGL3-Renilla  plasmid  (internal 
control).  All  experiments  were  performed  independently  3  times  in  triplicates  and  all 
measurements were made 24 h after transfection. 
These experiments revealed that the presence of an upstream promoter element for both 

























Western blot experiment using patient biopsy samples from individual AML patients (2-5 x 
10
6  cells),  along  with  soluble  lysates  prepared  from  NTERA2  and  SEM  cells.  Blots  were 
stained with the C-terminal antibody against NANOG. Only 4 out of 10 investigated leukemia 
samples had enough cells to perform this experiment. The displayed patients all express 






































blot: C-terminal antibody @ NANOG